Methotrexate Pharmacology and Resistance in Childhood Acute Lymphoblastic Leukemia
- 1 January 1996
- journal article
- review article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 21 (5-6), 359-368
- https://doi.org/10.3109/10428199609093433
Abstract
Impressive gains have been made in the therapy of childhood acute lymphoblastic leukemia (ALL) in recent years such that remissions today are commonly achieved in up to 95% of patients and long term disease-free survival rates approach 70%. Methotrexate is a key component in ALL consolidation and maintenance therapies and is administered intrathecally in the prophylaxis and treatment of central nervous system leukemia. Critical determinants of methotrexate sensitivity and resistance (di-hydrofolate reductase levels, methotrexate membrane transport, methotrexate polyglutamylation) previously described in cultured cells have recently been identified in lymphoblasts from children with ALL. Heterogenous expressions of increased dihydrofolate reductase or impaired methotrexate transport can be detected in both diagnostic and relapsed ALL specimens by flow cytometry with fluorescent methotrexate analogues. Lymphoblasts from children with ALL synthesize long chain polyglutamates and correlations have been established between the accumulation of methotrexate polyglutamates in ALL blasts and characteristic patient prognostic features. Variations in methotrexate polyglutamate accumulation may reflect changes in polyglutamate synthetic or degradative enzymes, or may be secondary to changes in methotrexate influx or dihydrofolate reductase levels. Other critical elements in treatment response to methotrexate include the dose and route of methotrexate administration, its catabolism to 7-hydroxymethotrexate, and the rate of methotrexate plasma clearance. A unique relationship exists between chromosome 21 and ALL leukemogenesis, and response to treatment including methotrexate. A better understanding of the molecular bases of methotrexate response and the development of methotrexate resistance in childhood ALL should facilitate further improvements in the effectiveness of methotrexate-based chemotherapy for this disease.Keywords
This publication has 37 references indexed in Scilit:
- Assignment of the Human Folate Transporter Gene to Chromosome 21q22.3 by Somatic Cell Hybrid Analysis and in Situ HybridizationBiochemical and Biophysical Research Communications, 1995
- Molecular Cloning of the Human Placental Folate TransporterBiochemical and Biophysical Research Communications, 1995
- Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.JCI Insight, 1994
- Central Nervous System Pharmacology of Antileukemic DrugsJournal of Pediatric Hematology/Oncology, 1989
- Interactions between 7-hydroxymethotrexate and folinic acid in RAJI cells, in vitroCancer Letters, 1988
- Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemiaThe Journal of Pediatrics, 1987
- Methotrexate bioavailability after oral and intramuscular administration in childrenThe Journal of Pediatrics, 1987
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaThe New England Journal of Medicine, 1986
- 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.JCI Insight, 1976
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)The New England Journal of Medicine, 1948